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2 
Abstract 
 
Aiming to combine the flexibility of Brucella Lumazine synthetase (BLS) to adapt different 
protein domains in a decameric structure and the capacity of BLS and flagellin to enhance 
the immunogenicity of peptides that are linked to their structure, we generated a chimeric 
protein (BLS-FliC131) by fusing flagellin from Salmonella in the N-termini of BLS. The 
obtained protein was recognized by anti-flagellin and anti-BLS antibodies, keeping the 
oligomerization capacity of BLS, without affecting the folding of the monomeric protein 
components determined by circular dichroism. Furthermore, the thermal stability of each 
fusion partner is conserved, indicating that the interactions that participate in its folding are 
not affected by the genetic fusion. Besides, either in vitro or in vivo using TLR5 deficient 
animals we could determine that BLS-FliC131 retains the capacity of triggering TLR5. The 
humoral response against BLS elicited by BLS-FliC131 was stronger than the one elicited 
by equimolar amounts of BLS + FliC. Since BLS scaffold allows the generation of hetero-
decameric structures, we expect that flagellin oligomerization on this protein scaffold will 
generate a new vaccine platform with enhanced capacity to activate immune responses. 
 
Keywords: BLS, Flagellin, scaffold, TLR5 
 
In this work we have combined BLS and flagellin, two promising immunogenic molecules that 
fused as a chimera, BLS-FliC131, conserve the structural and biological characteristics of each of 
its components and can be exploited as vaccine carrier/adjuvant.  
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Introduction 
 
The increasing understanding on microbial biology, pathogenesis and host immunobiology 
in combination with development of powerful screening tools and predictive bioinformatics 
have shifted vaccine development from exclusively empirical approaches towards rational 
design.1,2 Initial vaccines were mainly based on the use of attenuated or inactivated whole 
microorganisms. A new generation of vaccines based on recombinant components has 
followed, moving towards chemically defined vaccines. The ideal vaccine should keep the 
highest protective capacity eliciting as few adverse effects as possible. Chemically defined 
vaccines have the best safety profiles, but they have to face the challenge of eliciting 
protection using just one or a few components of a pathogen.3 Immunogenicity of single 
proteins or peptides is much lower than whole microorganisms. To override this 
disadvantage, the selection of the best immunogen(s) for each pathogen as well as 
combining it with appropriate adjuvants becomes crucial. The discovery of several families 
of innate response receptors has refreshed the adjuvant field, providing a rational 
background for the selection of compounds with adjuvant properties.4 
Flagellin is the major structural protein of Gram-negative bacteria, being also a ligand of 
TLR55 and of intracytosolic innate receptors of the NOD-like receptor (NLR) family.6 It 
exhibits strong adjuvant properties when administered by different routes7 being much 
more efficient when is covalently linked to the immunogen.8 Consequently, flagellin has 
been proposed as a platform for vaccine development being successfully used in proof of 
concept studies using several model infections, including Yersinia pestis, Influenza, 
Clostridium difficile, and Plasmodium vivax among others.9–12 Considerable experimental 
evidence supports the role of flagellin in the enhancement of immunogenicity. It has been 
hard to accurately define the structure of flagellin monomer, since they tend to polymerize 
in aqueous solution. This was overcome using a fragment of flagellin lacking the N and C 
termini (called F41 in Salmonella).13 
The enzyme lumazine synthase from Brucella spp. (BLS) is a highly immunogenic 
protein,14–16 and behaves as a potent oral or systemic immunogen when injected as a 
protein or as a DNA vaccine.17 BLS has been extensively used as a carrier for peptides 
and proteins being a proven successful platform for antigen presentation to the immune 
system for vaccine development.16–19 Several BLS features make this molecule an 
attractive protein scaffold for multiple display. First, the oligomer is highly stable to 
chemical and thermal denaturation. Second, it can be reversibly unfolded and 
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reassembled in different conditions. Third, its 10 N-termini are excellent acceptors for 
foreign polypeptides given their exposed and flexible nature. Finally, recombinant BLS can 
be expressed at high levels in prokaryotic and eukaryotic cells and is highly immunogenic, 
an essential property for vaccine development. BLS folds as stable dimers of pentamers,20 
and has been shown to allow the insertion of foreign peptides or proteins at its N-terminus 
without disrupting its general folding.18,19,21 The presentation of BLS to the immune system 
in a highly ordered three-dimensional array enhances the immunogenicity of the 
heterologous peptides.18,19,22 BLS induces the functional and phenotypic maturation of 
dendritic cells (DCs) via TLR4, stimulating the secretion of proinflammatory cytokines and 
chemokines.23 BLS induces the cross presentation of covalently attached peptides and 
generates a strong and long-lasting humoral immune response without adjuvants.22 BLS 
elicits an antitumor immune response via TLR4 and has a direct effect on tumor growth 
and mice survival dependent on TLR4 from B16 melanoma.24 
 
With the aim of combining the flexibility of BLS to adapt different protein domains in a 
heterodecameric structure25 and the capacity of BLS and flagellin to enhance the 
immunogenicity of its attached peptides, we generated a chimeric protein (BLS-FliC131) 
by fusing flagellin from Salmonella in the 10 N-termini of BLS. Since the anti-flagellin 
antibodies generated upon several administrations could hamper its adjuvanticity,26 we 
used a flagellin with a deletion in the D2-D3 antigenic domains.27 Overall, this construct 
keeps the oligomerization capacity of BLS, without affecting the folding of the monomeric 
protein components. Furthermore, this fusion protein retains the capacity of triggering 
TLR5 enhancing the humoral response against BLS. We expect that flagellin 
oligomerization on this protein scaffold will generate a new vaccine platform with enhanced 
capacity to activate immune responses.  
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Results 
 
BLS-FliC131 chimeric protein keeps folding properties of FliC C131 and BLS and is 
decameric in solution. 
Using the same strategy described in Laplagne et al18 for the construction of chimeras of 
BLS and small peptides, we replaced the coding sequence of the first eight residues of the 
N-terminal end of BLS with the coding sequence of FliC C131. The production and 
purification of the chimera was carried out as described in the Methods section. SDS-
PAGE analysis along expression and purification process of the chimeric protein BLS-
FliC131 indicated that the monomeric protein has the expected molecular weight of 52 
kDa. The BLS-FliC131 chimeric protein is recognized by previously described anti-flagellin 
and anti-BLS monoclonal antibodies,14,28 as shown by Western blot (Fig. 1).  
Considering the biophysical properties of BLS we expected the BLS-FliC131 chimera to be 
decameric. Based on the structure of the F41 fragment of Salmonella enterica flagellin and 
of BLS, we constructed a schematic three-dimensional model of the BLS-FliC131 chimera 
(Fig. 2). In order to determine the oligomeric state of the BLS-FliC131 chimera we 
performed a static light scattering assay coupled to size-exclusion chromatography (SEC-
SLS) of BLS, FliC C131 and BLS-FliC131 (Fig. 3). BLS eluted as two peaks. The major 
one corresponds to a molecular weight of 176 kDa, which is compatible with the expected 
value for the decamer, 174 kDa. The presence of the extra peak of higher molecular 
weight (not determined) indicates a tendency to form higher n-oligomers in the conditions 
of the experiment, not reported previously. FliC C131 eluted as a single and symmetric 
peak with a molecular weight of 30 kDa. As the theoretical molecular weight is 35 kDa, the 
result indicates that FliC C131 is a monomer in solution. Taking into account that FliC 
C131 lacks the D3 domain that favors the protofilament formation, we expect FliC C131 to 
be a monomer or a low n-oligomer. As for the BLS-FliC131 chimera, there is a peak 
around 500kDa compatible with the chimeric decamer, whereas most part of the sample 
was not resolved by the column, possibly corresponding to high molecular weight 
aggregates.  For all in vivo experiments performed afterwards, 500 kDa fraction was used. 
 
The secondary structure of BLS and FliC C131 are partially preserved in the BLS-FliC131 
chimera. 
We compared the far UV-circular dichroism spectra of BLS, FliC C131 and BLS-FliC131 
(Fig. 4). As already reported,20 BLS presents two minima, the main at 220 nm and the 
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other at 211 nm. FliC C131 also presents two minima, being the main located at 208 nm 
and the other at 220 nm. The results show that the spectrum of BLS-FliC131 chimera 
partially resembles the sum of spectra of the isolated BLS and FliC C131. The 
experimental and expected spectra are practically identical from 215 nm to 254 nm, while 
they differ in the range from 200 nm to 215 nm. Taking into account that most of the signal 
within this last range correspond to FliC C131, the results indicate that BLS structure 
seems to be preserved in the BLS-FliC131 chimera while FliC C131 does not fully fold in 
the context of the chimera as the isolated FliC C131. 
 
The BLS-FliC131 chimera keeps the thermal denaturation and the reversibility of the 
thermal unfolding behaviors of the isolated BLS and FliC C131.  
The stability of the BLS-FliC131 chimera to thermal denaturation was followed by 
measuring the molar ellipticity at 220 nm as a function of increasing temperature, 
compared to the isolated BLS and FliC C131 (Fig. 5). As stated before,20 BLS shows a 
sharp decrease of ellipticity between 85 and 95°C with an apparent midpoint of the thermal 
denaturation (Tm) of 88.6°C. The loss of secondary structure is not recovered after cooling 
of the samples back to 25°C (Fig. 6), indicating that an irreversible unfolding of BLS takes 
place under these conditions. On the other hand, FliC C131 presents an apparent Tm of 
34.9°C, however preserves most of the secondary structure after denaturation. BLS-
FliC131 chimera presents two phases in the thermal denaturation, with apparent Tm 
similar to the ones of the isolated BLS and FliC C131, 87.4°C and 35.7°C. Interestingly, 
the chimera presents a partial reversibility of the thermal unfolding. The results indicate 
that the BLS-FliC131 chimera keeps the thermal denaturation and the reversibility of the 
thermal unfolding behaviors of the isolated BLS and FliC C131.  
 
BLS-FliC131 chimeric protein can activate innate immunity either in vitro or in vivo. 
In order to assess the biological properties of the generated chimeric protein, we first used 
a Caco2 luciferase reporter cell line generated in our laboratory.26 This system is highly 
sensitive to TLR5 activation, whereas TLR4 stimulation does not induce changes in this 
cell type.26,29 It was observed that 5 µg/mL of BLS-FliC131 chimera as well as the 
equimolar amount of FliC C131 (3.5 µg/mL) are strong agonists of this in vitro system [Fig. 
7(A)], whereas treatment with BLS or LPS did not induce changes to the basal activity. 
The capacity of BLS-FliC131 fusion protein to trigger an innate response was also tested 
in vivo in a mouse model. BLS-FliC131 chimeric protein induced a significant recruitment 
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of neutrophils to the peritoneal cavity or the bronchoalveolar space 24 h post-treatment 
[Fig. 7(B)]. Comparable results were obtained upon FliC C131 treatment whereas BLS 
treatment showed a modest, statistically not significant change. These results indicate that 
BLS-FliC131 fusion protein retains the capacity to trigger TLR activation comparable to 
their individual components.  
 
BLS-FliC131 capacity to induce innate response markers in vivo is highly dependent on 
TLR5. 
 In order to determine the capacity of BLS-FliC131 fusion protein to activate the innate 
response in vivo, we treated mice i.v. and measured levels of selected innate response-
associated cytokines in plasma 2 h after stimulation.  
IL6 levels were increased in wt animals treated with LPS, FliC C131 or BLS-FliC131 
chimera compared with control group (Fig. 8A). Interestingly, in TLR4 deficient mice, FliC 
C131 and BLS-FliC131 treatments, but not LPS, enhanced serum IL6. As expected, in 
TLR5 deficient mice treated with FliC C131 there was not change in IL6 levels whereas 
opposite results were obtained in those animals treated with LPS and BLS-FliC131.  
Similar results were obtained when detecting CCL20 serum levels, which are mainly 
contributed by liver stimulation.30 BLS-FliC131 treatment induced a rise in CCL20 serum 
levels in wt and TLR4 deficient mice, with only slight changes in TLR5 deficient mice. As 
expected, no changes in CCL20 levels were observed by treatment with LPS and FliC 
C131 in TLR4 and TLR5 deficient mice, respectively [Fig. 8(B)]. 
In the case of IL22, it was reported that flagellin treatment generates a peak in IL22 serum 
levels in a TLR5-dependent fashion, this being dependent of mucosal and splenic CD11c+ 
DCs and innate lymphoid cells. On the other hand, LPS administration generates less 
important changes in IL22 serum levels.31 In agreement with this report, no changes were 
observed by any treatment in TLR5 deficient mice [Fig. 8(C)], whereas FliC C131 and 
BLS-FliC131 induced a rise in this cytokine in wt as well as in TLR4 deficient mice. In the 
case of LPS, a rise in IL22 was observed only for wt mice, whereas no response was 
measurable in TLR4 deficient animals [Fig. 8(C)]. Altogether, these results indicate that in 
vivo BLS-FliC131 retains its capacity to signal through TLR5 since their activating 
capacities were conserved in TLR4 or wt mice, while being mainly affected in TLR5 
deficient mice.  
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Immunogenicity of BLS is enhanced in the BLS-FliC131 fusion protein. 
Anti-BLS antibody titers were determined in mice immunized twice in different conditions, 
using an equimolar low amount of antigen in each treatment. Notably, animals immunized 
with BLS-FliC131 fusion protein elicited higher anti-BLS IgG than the other groups 
(p<0.05; Fig. 9), showing that physical attachment of BLS to flagellin enhances the 
capacity of BLS to generate antibody response.  
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Discussion 
 
We report the generation of a fusion protein between FliC from Salmonella and BLS from 
Brucella that has conserved the main features of each of its constitutive polypeptides, 
basically the capacity to generate a decameric structure and to activate innate response. 
We selected a flagellin variant devoid of exposed D2 and D3 domains (FliC C131) which 
are highly antigenic regions.27 The trigger of anti-flagellin antibodies may constitute a 
problem for repeated in vivo treatment, since it has been shown that this response may 
impair TLR5 activation.26 BLS has the capacity to act as a vaccine carrier, having a 
compact decameric quaternary structure and allowing the addition of antigenic 
peptide/proteins in its N-terminus.18,19,21 We have shown here that the BLS-FliC131 
chimera (a) can adopt decameric structure; (b) fully keeps the secondary structure of BLS 
and partially the one of FliC C131; (c) has a thermal denaturation behavior that keeps the 
features of both isolated BLS and FliC C131; (d) presents a partial reversibility of the 
thermal unfolding, behaving as an intermediate case between the isolate BLS and FliC 
C131 (e) keeps the capacity to trigger TLR5-activation and is highly immunogenic.  
It has been shown that a stronger response is obtained if the antigen is attached to BLS,17 
and this have been the basis for the development of several applications using BLS as 
vaccine carrier.17,19,22,24,32–35 Furthermore, it has been shown that through changes in urea 
concentration, reassociation between different BLS-peptide fusion proteins, a 
heterodecameric structure can be obtained.25 This may be an interesting application for 
the fusion protein described here, allowing to produce mixed BLS chimeras containing 
BLS-FliC and BLS-antigen of interest fusion proteins. 
Beyond the structural analysis indicating that FliC C131 domain in the fusion protein has 
partially retained the folding of native FliC C131 (Fig. 4), we could demonstrate that it has 
kept the capacity to trigger innate immunity due to its interaction with TLR5 (Fig. 7). It has 
been recently shown that TLR5 signaling is triggered by a 2:2 interaction with two different 
flagellin subunits that are not physically linked.36,37 We are currently performing 
experiments to determine the stoichiometry of the interaction established between the 
BLS-FliC131 fusion protein and TLR5. Different in vivo results indicate that this capacity to 
trigger TLR5 signaling is also functional in this situation (Fig. 8), specially the capacity to 
trigger IL22 rise in serum, which has been associated to TLR5 dependent dendritic cell 
activation in vivo.31 
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There is extensive evidence showing that covalent attachment of antigens to flagellin 
enhances the antibody and cellular response against the antigen.8,38–40 This is also the 
case of the construction reported herein, since enhanced anti-BLS IgG response was 
observed in animals immunized with BLS-FliC131 chimera using protein amounts that 
have shown weak antibody response against BLS.16 Notably, when BLS was not attached 
to flagellin (BLS+FliC C131 condition), anti-BLS antibody response was lower than in the 
case of BLS-FliC131 immunized animals (Fig. 9). It has been shown that uptake and 
processing is enhanced when the antigen is attached to a TLR ligand,41 although the 
cellular mechanisms responsible for this activity has not been fully elucidated. BLS-
FliC131 fusion protein is also an interesting tool to study the contribution of TLRs to these 
processes, which is subject of current investigations. 
In conclusion, we have generated a chimeric BLS-FliC131 protein that keeps structural 
and biological features and that could be exploited as vaccine carrier/adjuvant combining 
the characteristics of two promising candidate molecules. 
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Materials & Methods 
 
Gene cloning and protein expression and purification 
 
Flagellin C131 variant from Salmonella typhimurium. The flagellin C131 from Salmonella 
typhimurium (strain LT2 / SGSC1412 / ATCC 700720) corresponds to the deletion version 
FliC∆202-369 of flagellin (Uniprot code: P06179). The construct was cloned in pET11a 
vector (Novagen). Escherichia coli BL21(DE3) competent cells (Stratagene, La Jolla, 
California, USA) were transformed with the expression plasmid mentioned above. A 
preculture was grown overnight in LB medium with 100 µg/mL ampicillin at 37°C with 
agitation (200 rev/min) and then diluted to 1:100 and grown to an absorbance (at 600 nm) 
of 0.6. At this point, isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to a final 
concentration of 1 mM and the cultures were further incubated overnight at 20°C with 
agitation (200 rev/min). The flagellin C131 variant was purified as previously described.1 
Briefly, the bacteria were centrifuged at 5000g for 10 min at 4°C. Pellets were 
resuspended and sonicated. The cytosolic fraction was filtered and saturated with 60% 
ammonium sulfate (Sigma-Aldrich). The precipitated materials were recovered by 
centrifugation, solubilized in 20 mM Tris-HCl pH 7.5 and then dialyzed. The protein was 
further purified by anion exchange chromatography (Bio-Rad). 
 
BLS (Brucella lumazine synthase). The cloning, recombinant expression, and purification 
of BLS were described previously.18,42 Briefly, the BLS gene cloned in pET11a vector 
(Novagen) was transformed and expressed as inclusion bodies on E. coli BL21 (DE3) 
strain. The inclusion bodies were solubilized by overnight agitation in 50 mM Tris-HCl, 5 
mM EDTA, 8 M urea, pH 8.0 buffer at room temperature. The solubilized material was 
refolded by dialysis against PBS buffer (20 mM phosphate pH 7.4, 150 mM sodium 
chloride) containing 1 mM dithiothreitol (DTT). This preparation was purified in a Mono-Q 
column in a fast performance liquid chromatography system (Amersham Bioscience, 
Uppsala, Sweden) using a linear gradient of sodium chloride between 0 and 1 M in 50 mM 
Tris-HCl pH 8.5 buffer. The BLS-enriched peak was further purified on a Superdex-200 
column by elution with PBS containing 1mM phenylmethanesulfonyl fluoride or 
phenylmethylsulfonyl fluoride (PMSF) and 1 mM DTT. The purity of the BLS preparation 
was determined by SDS-PAGE 15% (w/v). 
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BLS-FliC131 fusion protein. To produce the plasmid pFliC-BLS the FliC∆202-369 coding 
sequence was cloned upstream to the BLS gene in a previously generated pET11a vector 
containing the BLS sequence (Gen-Script Corporation). FliC C131 and BLS sequences 
were linked through a pentapeptide linker of sequence glycine-serine-glycine-serine-
glycine-serine. E. coli BL21(DE3) competent cells (Stratagene, La Jolla, California, USA) 
were transformed with the expression plasmid mentioned above. A preculture was grown 
overnight in LB medium with 100 µg/mL ampicillin at 37°C with agitation (200 rev/min) and 
then diluted to 1:100 and grown to an absorbance (at 600 nm) of 0.6. At this point, IPTG 
was added to a final concentration of 1 mM and the cultures were further incubated 
overnight at 20°C with agitation (200 rev/min). The recombinant chimera was purified from 
inclusion bodies. The inclusion bodies were solubilized by overnight agitation in 50 mM 
Tris-HCl, 5 mM EDTA, 8 M urea, pH 8.0 buffer at room temperature. Afterwards, urea was 
gently removed by stepwise dialysis against Tris-HCl-EDTA buffer containing 4M urea and 
then against PBS buffer. The solubilized protein was purified by affinity chromatography 
using monoclonal anti-flagellin antibodies.28 Briefly, the 2B3C5 antibody was conjugated to 
an activated resin (NHS-Activated Sepharose 4 Fast Flow G & E) according to the 
manufacturer’s instructions. The protein was incubated within a TBS buffer (50 mM Tris-
HCl pH 8.4, 150 mM sodium chloride) with the resin at 4°C, centrifuged at 2500 rpm for a 
minute, washed with TBS, eluted with 100 mM glycine pH 3 and neutralized with 1 M Tris 
pH 8.  
Lastly, the three proteins were depleted of lipopolysaccharides (LPS) using a polymyxin B 
column (Pierce) and dialyzed in PBS buffer and 1 mM PMSF. The quality of the final 
preparations was checked by SDS–PAGE and UV spectrophotometry. The concentration 
of the protein was estimated using the absorbance at 280 nm and the molar extinction 
coefficient calculated from the sequence using the ProtParam tool from the Expasy server 
(http://web.expasy.org/protparam/). 
 
Measurement of endotoxin activity 
The Limulus amebocyte lysate test was performed using the Gel-clot method for the 
detection and quantification of Gram-negative bacterial endotoxins (LPS) (Pyrotell), 
following the manufacturer’s instructions. The detection limit of the assay was 0.03 EU/mL 
(0.003 ng/mL). 
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Western blot analysis 
10 µg of total proteins were separated by 12% SDS–PAGE and transferred to 
nitrocellulose membrane (Amersham; GE Healthcare). Mouse monoclonal antibody to 
flagellin (2B3C5) or to BLS were used as the primary antibody;14,28 and appropriate HRP-
conjugated anti-mouse (Bio-Rad) was used as the secondary antibody.  
 
Caco2-CCL20-luc reporter cell assays 
Caco-2 cells stably transfected with a luciferase reporter construction under the control of 
CCL20 promoter (Caco-2 ccl20:luc) were previously described.26 Confluent Caco-2 
ccl20:luc cells growth on 48-well plates were treated with equimolar concentrations of FliC 
C131 (0.7 µg/mL), BLS (0.3 µg/mL) or BLS-FliC131 (1 µg/mL). After 6 h cells were 
collected and luciferase activity was evaluated using the Luciferase Assay Kit (Promega, 
USA) following manufacturer’s instructions using a Luminoskan TL Plus luminometer. 
 
Size exclusion chromatography - Static light scattering measurements 
The average molecular weight (MW) of BLS, FliC C131 and BLS-BLS-FliC131 were 
determined on a Precision Detectors PD2010 90º light scattering instrument tandemly 
connected to a high-performance liquid chromatography and a LKB 2142 differential 
refractometer. The column used was Superose 6 GL 10/300 (GE Healthcare). Five 
hundred µL of each purified protein were injected into the column, and the 
chromatographic runs were performed with PBS buffer (20 mM phosphate pH 7.4, 300 mM 
sodium chloride) under isocratic conditions at a flow rate of 0.4 mL/min at 25ºC. The 
concentration of the injected samples was ~1 mg/mL. The MW of each sample was 
calculated relating its 90° and RI signals, using the software Discovery32. BSA (MW: 66.5 
kDa) was used as a standard. 
 
Circular Dichroism 
The circular dichroism (CD) spectra of FliC C131, BLS and BLS-FliC131 were recorded in 
the far UV (200-254 nm) using a Jasco J-815 spectropolarimeter equipped with a Peltier 
temperature control system, using a 2 mm path length quartz cell. A scanning speed of 
100 nm/min, a response time of 2 s, a data pitch of 0.2 nm, and a band width of 2 nm were 
set. For each sample, three spectra were recorded and the result presented as the 
average spectrum to reduce background noise. Data were collected at 25ºC in PBS buffer 
containing 1 mM PMSF. Protein concentration was 15 µM. The samples were incubated 
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for 15 min at 25ºC before taking CD measurements. Raw data were converted to molar 
ellipticity using the following relationship: 
[θ](deg · cm2 · dmol-1) = θ (mdeg)/10 · L (cm) · [M](M) 
where θ is the raw signal in millidegrees, L is the path length in cm and [M] is the protein 
concentration in molar units. 
 
Thermal Denaturation Monitored by CD 
The heat-induced denaturation of FliC C131, BLS and BLS-FliC131 in PBS buffer 
containing 1 mM PMSF was followed by measuring the CD signal at 220 nm on the 
spectropolarimeter mentioned above at different temperatures. The samples were slowly 
heated by increasing the temperature with the Peltier system. The range of temperature 
scanning was 20-100°C at a speed of 4°C/min. The molar ellipticity at 220 nm was 
measured every 0.1°C. The data was fitted to sigmoidal functions and inflection points 
were calculated using GraphPad Prism software. 
 
Model of the BLS-FliC131 structure 
A schematic model of the BLS-FliC131 chimera was performed based on the 
crystallographic coordinates of BLS, PDB code: 1T13 and the electron microscopy 
structure of the Salmonella enterica Flagellin, PDB code: 3A5X. The model was made by 
simply putting in close proximity the C-terminus of the portion of the 3A5X coordinates that 
correspond to the FliC C131 to the N-terminal end of the 1T13 coordinates, using the 
program PyMOL (http://www.pymol.org). 
 
Cell recruitment assays 
Bronchoalveolar lavage (BAL) was performed as described.43 Briefly, C57BL/6 mice  were 
stimulated with equimolar amounts of FliC C131 (0.7 µg), BLS (0.3 µg) or BLS-FliC131 (1 
µg) diluted in PBS given by intranasal route. After 6 h post-treatment, animals were 
euthanized by intraperitoneal pentobarbital injection and the thoracic cavity was dissected, 
the blood in the lungs was cleared by perfusing PBS at room temperature through the 
heart’s right lobe until the lungs became pale. To perform the BAL, the trachea was 
partially cut and 1 ml of sterile PBS containing 0.1% BSA was flushed into the lungs and 
then withdrawn. This procedure was repeated 3 times.  
For analysis of cell recruitment to the abdominal cavity, animals were treated i.p. with 
equimolar amounts of FliC C131 (0.7 µg), BLS (0.3 µg) or BLS-FliC131 (1 µg) diluted in 
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PBS. After 6 h, peritoneal fluid was obtained from mice by peritoneal wash and centrifuged 
at 450g for 10 min. The supernatant fluid was discarded and pelleted cells were analyzed 
by flow cytometry. 
Cells from the BAL or peritoneal wash were stained with fluorescent antibodies for 1 h at 
4ºC, followed by flow cytometry analysis using a FACSCalibur from Becton Dickinson. The 
FITC-, PE-, APC-, and PerCP- conjugated monoclonal specific antibodies for CD11c 
(clone N418, hamster IgG: eBioscience, San Diego, CA, USA), Gr1 (clone RB6-8C5, Rat 
IgG2b: eBioscience), CD11b (clone M1/70.15, Rat IgG2b: Caltag Laboratories, CA, USA), 
Ly-6G (clone 1A8, Rat IgG2a: BD Pharmingen) and Ly6C (AL-21, Rat IgM: BD 
Pharmingen) were used to label the cells. Polymorphonuclear cells were identified as 
CD11c- CD11b+Ly6G+ GR1+ cells. 
 
Serum cytokine analysis 
Female C57BL/6J (6-8 weeks old) mice were obtained from Janvier laboratories (St. 
Berthevin, France). TLR424 and TLR544 knockout mice were maintained in a specific 
pathogen-free facility (Leloir Institute and Institut Pasteur de Lille, respectively). Equimolar 
amounts of FliC C131 (0.7 µg), BLS (0.3 µg) or BLS-FliC131 (1 µg) diluted in PBS were 
given by the intravenous route. LPS (1µg) from E. coli (serotype 0111:B4, Invivogen) or 
PBS were used as control. Blood samples were collected 2 h after treatment and clotted at 
room temperature, with the serum then being separated by centrifugation. All samples 
were stored at -80°C prior to analysis. IL-6, IL-22 and CCL20 concentration in serum were 
measured using ELISA kits (eBioscience, USA) following manufacturer’s instructions. All 
experiments complied with current national and institutional regulations and ethical 
guidelines (B59-350009 – Institut Pasteur de Lille). 
  
Immunization and anti-BLS antibody determination 
C57BL/6J mice were vaccinated i.p. on days 1 and 21 with LPS-depleted BLS (0.3 µg) ± 
LPS-depleted FliC C131 (0.7 µg) or with LPS-depleted BLS-FliC131 fusion protein (1 µg). 
At day 30, blood was extracted from the submandibular sinus and anti-BLS antibodies 
were determined by indirect ELISA in serum as previously described.16 
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Statistical analysis 
Results were expressed as the mean+SD. Levels of significance were determined using 
two-tailed Student’s t test, and a confidence level of greater than 95% (p<0.05) was used 
to establish statistical significance. 
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Figure legends 
 
Figure 1. BLS-FliC131 chimeric protein conserves immunochemical reactivity.  
Western blot analysis using anti-FliC and anti-BLS monoclonal antibodies. Lane 1: BLS-
FliC131 chimera, Lane 2: FliC C131, Lane 3: BLS. MW: molecular weight marker.  
 
Figure 2. Three-dimensional structure of the decameric BLS (PDB code: 1T13), the 
Flagellin 131 (PDB code: 3A5X) and a model of BLS-FliC131 chimera. The structures are 
represented as surface and for BLS and Flagellin also as cartoon. The expected MW 
values are indicated.  
 
Figure 3. Static light scattering coupled to size exclusion chromatography. BLS (blue), FliC 
C131 (red) and BLS-FliC131 (green) were subjected to SEC coupled to a light-scattering 
instrument connected in tandem to a differential refractometer detector. The MW values 
estimated by the relation of scattering/RI signals are indicated above each curve. The 
values following after an asterisk correspond to the expected MW.  
 
Figure 4. Far UV circular dichroism. Comparison of the far UV-CD spectra of BLS (blue), 
FliC C131 (red), BLS-FliC131 (green) and the sum of BLS and FliC C131 spectra (black 
dashed). Results are representative from three different experiments. 
 
Figure 5. Thermal denaturation monitored by circular dichroism. The heat-induced 
denaturation curve of BLS (blue), FliC C131 (red), BLS-FliC131 (green). CD signal was 
measured at 220 nm. Dashed lines indicate the inflection points of each curve. Results are 
representative from two different experiments. 
 
Figure 6. Reversibility of the thermal unfolding monitored by circular dichroism. CD spectra 
of BLS (blue), FliC131 (red), BLS-FliC131 (green) at 25ºC before (continuous line) and 
after (dashed lines) the thermal denaturation experiment. Results are representative from 
two different experiments. 
 
Figure 7: Fusion protein keeps the capacity to trigger innate response either in vitro or in 
vivo. A. Activity on Caco2-Luciferase reporter cell line. Cells were treated with different 
stimuli and luciferase activity was measured on cell lysate 6 h post-stimulation. Results are 
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expressed as fold-increase with respect to non-treated control. Results are representative 
from three different experiments. (***p<0.005 two way ANOVA followed by Tuckey test).  
B. Recruitment of neutrophils when administered either i.p. or i.n. C57BL/6J mice were 
treated with different stimuli and cells recovered by broncheoalveolar or peritoneal wash 
and analyzed by flow cytometry upon immunostaining. Results are expressed as 
percentage of polymorphonuclear cells (CD11c- CD11b+Ly6G+ GR1+). Results are 
representative from three different experiments. (***p<0.005 two way ANOVA followed by 
Tuckey test). 
 
Figure 8: BLS-FliC131 has the capacity to trigger innate response activation in vivo in 
TLR4 and TLR5 deficient mice. Animals were stimulated i.v. with different treatments. 
Cytokines were determined in serum samples 2 h upon treatment by ELISA. Results are 
representative from two different experiments. (***p<0.005 two way ANOVA followed by 
Tuckey test). 
 
Figure 9: Immunogenicity of BLS is enhanced in the BLS-FliC131 fusion protein. Anti-BLS 
antibodies were determined by indirect ELISA in animals immunized twice with the 
different antigenic mixtures. Results are expressed as geometric mean of each group 
(n=5). Results are representative from two different experiments. 
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BLS-FliC chimeric protein conserves immunochemical reactivity.  
Western blot analysis using anti-FliC and anti-BLS monoclonal antibodies. Lane 1: BLS-FliC131 chimera, 
Lane 2: FliC131, Lane 3: BLS. MW: molecular weight marker  
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Three-dimensional structure of the decameric BLS (PDB code: 1T13), the Flagellin 131 (PDB code: 3A5X) 
and a model of BLS-FliC131 chimera. The structures are represented as surface and for BLS and Flagellin 
also as cartoon. The expected MW values are indicated.  
Figure 2  
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Figure 3. Static light scattering coupled to size exclusion chromatography. BLS (blue), FliC C131 (red) and 
BLS-FliC131 (green) were subjected to SEC coupled to a light-scattering instrument connected in tandem to 
a differential refractometer detector. The MW values estimated by the relation of scattering/RI signals are 
indicated above each curve. The values following after an asterisk correspond to the expected MW.  
Figure 3  
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Far UV circular dichroism. Comparison of the far UV-CD spectra of BLS (blue), FliC131 (red), BLS-FliC131 
(green) and the sum of BLS and FliC131 spectra (black dashed). Results are representative from three 
different experiments.  
Figure 4  
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Thermal denaturation monitored by circular dichroism. The heat-induced denaturation curve of BLS (blue), 
FliC131 (red), BLS-FliC131 (green). CD signal was measured at 220 nm. Dashed lines indicate the inflection 
points of each curve. Results are representative from two different experiments.  
Figure 5  
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Reversibility of the thermal unfolding monitored by circular dichroism. CD spectra of BLS (blue), FliC131 
(red), BLS-FliC131 (green) at 25 ºC before (continuous line) and after (dashed lines) the thermal 
denaturation experiment. Results are representative from two different experiments.  
Figure 6  
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Fusion protein keeps the capacity to trigger innate response either in vitro or in vivo. A. Activity on Caco2-
Luciferase reporter cell line. Cells were treated with different stimuli and luciferase activity was measured on 
cell lysate 6 h post-stimulation. Results are expressed as fold-increase with respect to non-treated control. 
Results are representative from three different experiments. (***p<0.005 two way ANOVA followed by 
Tuckey test).  
B. Recruitment of neutrophils when administered either i.p. or i.n. C57BL/6J mice were treated with different 
stimuli and cells recovered by broncheoalveolar or peritoneal wash and analyzed by flow cytometry upon 
immunostaining. Results are expressed as percentage of polymorphonuclear cells (CD11c- CD11b+Ly6G+ 
GR1+). Results are representative from three different experiments. (***p<0.005 two way ANOVA followed 
by Tuckey test).  
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Figure 8: BLS-FliC131 has the capacity to trigger innate response activation in vivo in TLR4 and TLR5 
deficient mice. Animals were stimulated i.v. with different treatments. Cytokines were determined in serum 
samples 2 h upon treatment by ELISA. Results are representative from two different experiments. 
(***p<0.005 two way ANOVA followed by Tuckey test).  
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Figure 9: Immunogenicity of BLS is enhanced in the BLS-FliC131 fusion protein. Anti-BLS antibodies were 
determined by indirect ELISA in animals immunized twice with the different antigenic mixtures. Results are 
expressed as geometric mean of each group (n=5). Results are representative from two different 
experiments.  
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